AML1-ETO (RUNX1::RUNX1T1) FISH Test for AML-M2 in UAE | 700 AED | DHA Licensed

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The AML1-ETO FISH test detects the RUNX1::RUNX1T1 translocation characteristic of AML-M2, offering a definitive diagnosis and risk stratification with 99.9% analytical sensitivity. This test, performed on bone marrow aspirate obtained under sterile conditions within an accredited hospital setting, delivers results in 3–4 working days, enabling timely treatment decisions.

Feature	AML1-ETO FISH	Conventional Karyotyping
Precision	>99% target specificity with locus-specific probes	Chromosome-level resolution, may miss cryptic translocations
Methodology	Fluorescence In-Situ Hybridization (FISH) – ISO 15189	Chromosome banding analysis
Turnaround	3–4 working days	7–10 days
Sample	Bone Marrow Aspirate – Hospital Extraction Only	Bone Marrow only (requires metaphase cells) – Hospital Extraction Only

Physician Insight & Safety Protocols

Mr. Prabhakar Reddy Kalathoor (DHA Registration ID: 61713011), Specialist Diagnostic Radiology at DNA Labs UAE, notes: “Detection of the RUNX1::RUNX1T1 fusion via FISH provides a robust molecular marker for AML-M2 subclassification and prognostic assessment. However, therapeutic decisions must always integrate cytogenetic, morphological, and clinical findings within a multidisciplinary tumour board review.”

Medication Advisory

Do not alter, pause, or discontinue any prescribed chemotherapy, anticoagulant therapy, or supportive care regimen without explicit written instruction from your treating haematologist or oncologist.

Exclusion Criteria & Emergency Indicators

Active infection or cellulitis at the intended bone marrow puncture site – defer collection until complete resolution.
Uncorrected bleeding diathesis or severe thrombocytopenia (platelet count <20×10⁹/L) – requires haematology consultation prior to procedure.
A valid physician prescription from a DHA-licensed oncologist or haematologist is mandatory; this test is not intended for routine wellness or antenatal screening.

Seek emergency care immediately if you develop: fever exceeding 38.3°C, unexplained bruising or haemorrhage, sudden neurological deficit, or incapacitating bone pain.

Patient FAQ & Clinical Guidance

1. What does a positive AML1-ETO result mean for my AML treatment?

A positive result confirms the presence of the RUNX1::RUNX1T1 fusion transcript, classifying the leukaemia as core-binding factor AML-M2. This molecular subtype is generally associated with a favourable prognosis and excellent response to high-dose cytarabine-based consolidation therapy when combined with clinical and morphological correlation.

2. How is the bone marrow sample collected?

A qualified physician performs a bone marrow aspiration under strict aseptic technique within a licensed hospital procedure room. The sample is immediately transferred to the cytogenetics laboratory via temperature-controlled secure courier. Hospital extraction is mandatory; home phlebotomy is not available for this invasive specimen type.

3. Is a physician prescription required to proceed with this test?

Yes, a valid prescription from a DHA-licensed oncologist or haematologist is obligatory for all new diagnostic requests. For patients already enrolled in active monitoring protocols, the laboratory may accept a documented standing order from the treating physician in accordance with DHA regulatory guidelines.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates under DHA Facility License Number 1143 and complies fully with all applicable UAE federal data protection and health information governance frameworks. All patient genetic and clinical data are processed in strict adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Results are released only to the requesting physician or authorised healthcare provider via encrypted digital channels.

Clinical & Logistical Metadata

Test Name	AML1-ETO (RUNX1::RUNX1T1) FISH – Acute Myeloid Leukaemia M2 Subclassification
Price (AED)	700 AED
Turnaround Time	3–4 working days
Sample Type / Matrix	Bone Marrow Aspirate – Hospital Extraction Only
Methodology Used	Fluorescence In-Situ Hybridization (FISH) – ISO 15189 Accredited
ICD-10-CM Code	C92.0 – Acute myeloblastic leukaemia, AML-M2 subtype with t(8;21)(q22;q22) RUNX1::RUNX1T1
LOINC Code	33778-9 – RUNX1T1 (ETO)/RUNX1 (AML1) fusion, FISH
DHA Facility License & Laboratory Address Invariants	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE